Back to Hematology
Hematologyv2013 SpyropoulosEvidence-Based

IMPROVE Bleeding Risk Score

Assesses bleeding risk at hospital admission for acutely ill medical patients, particularly when considering anticoagulation therapy. The IMPROVE Bleeding Risk Score was developed from an international observational database of 15,156 patients across 52 hospitals in 12 countries to predict major bleeding and clinically relevant non-major bleeding within 14 days of admission. The cumulative incidence of major and non-major but clinically relevant in-hospital bleeding within 14 days of admission was 3.2%. This validated tool helps clinicians identify patients at high risk for bleeding complications and assess the risk-benefit ratio of pharmacological thromboprophylaxis. Patients with scores ≥7 have significantly greater rates of major bleeding (3.9% vs 1.2%) and should be carefully evaluated before anticoagulation.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The IMPROVE Bleeding Risk Score is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Score = Age points (0, 1.5, or 3.5) + Male gender (1) + Renal function points (0, 1, or 2.5) + Cancer (2) + Rheumatic disease (2) + Central venous catheter (2) + ICU/CCU (2.5) + Hepatic failure (2.5) + Platelet <50k (4) + Recent bleeding (4) + Active GI ulcer (4.5)

Clinical Pearls & Practice Notes

  • Developed from international IMPROVE database of 15,156 patients across 52 hospitals in 12 countries
  • Cumulative incidence of major and non-major but clinically relevant bleeding: 3.2% within 14 days
  • Score ≥7 associated with significantly higher bleeding rates: major bleeding 3.9% vs 1.2%
  • High-risk patients (≥7) had 5.6% clinically relevant bleeding vs 0.94% in low-risk
  • Designed specifically for acutely ill medical patients considering anticoagulation
  • Age categories: <40 years (0 pts), 40-84 years (1.5 pts), ≥85 years (3.5 pts)
  • Renal function based on GFR: ≥60 (0 pts), 30-59 (1 pt), <30 mL/min/m² (2.5 pts)
  • Platelet count threshold: ≥50,000/μL (0 pts), <50,000/μL (4 pts)
  • Active gastroduodenal ulcer carries highest individual risk factor weight (4.5 pts)
  • Score validated in multiple external cohorts with consistent discrimination
  • Consider non-pharmacologic thromboprophylaxis in high-risk patients
  • Enhanced bleeding monitoring recommended for high-risk patients requiring anticoagulation
  • May be used in conjunction with VTE risk assessment for comprehensive evaluation
  • Score calculated at hospital admission, reassess if clinical status changes

Evidence & Literature Citations

  1. Spyropoulos AC, Anderson FA Jr, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. doi: 10.1378/chest.10-1944.
  2. Hostler DC, Marx ES, Moores LK, et al. Validation of the International Medical Prevention Registry on Venous Thromboembolism bleeding risk model. Chest. 2016 Apr;149(4):1002-1009. doi: 10.1378/chest.15-2082.
  3. Rosenberg D, Eichorn A, Alarcon M, et al. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014 Nov 4;3(6):e001152. doi: 10.1161/JAHA.114.001152.
  4. Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. Thromb Haemost. 2017 May 3;117(5):801-808. doi: 10.1160/TH16-08-0631.

Score Interpretation Ranges

No Increased Risk0 – 6.9 pts

Score <7 points

Increased Risk7 – 30.5 pts

Score ≥7 points

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.